Skip to main content
. 2019 Nov 7;10:5076. doi: 10.1038/s41467-019-12846-7

Fig. 3.

Fig. 3

Validation of the biomarkers in PDCs and commercial cell lines. a The copy number variations (CNVs) of CDKN2A and CDKN2B were shown in eight ESCC PDCs and their corresponding tumor tissue. b Fifty percent growth inhibitory concentrations (IC50s) of palbociclib and ribociclib (LEE011) in eight ESCC PDCs with CDKN2A or CDKN2B loss or with no CNV of CDKN2A and CDKN2B. c The CNVs of CDKN2A and CDKN2B were illustrated in ten commercial cell lines. d IC50s of palbociclib and ribociclib in ten ESCC commercial cell lines with CDKN2A or CDKN2B loss or with no CNV of CDKN2A and CDKN2B. Error bars correspond to the standard deviation of IC50s. The comparisons between different groups of compound IC50s were performed using Student’s t test